Key facts
- It has raised $11.5M; the latest was Later Stage VC ($2.4M) in Oct 2024.
- Notable investors include Agoranov, Another Ventures, EIT Health, European Innovation Council (Belgium), FIST SA — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Aenitis
- ·The full record, as it builds
Funding rounds
No funding rounds for Aenitis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aenitis
Developer of a medical device designed to offer assistance for cell therapy preparations. The company's devices focus on cell therapy units and blood banks' challenges by developing bioprocessing medical devices dedicated to cell therapy manufacturing issues, including cell sorting, cell washing, and cell isolation, enabling the healthcare industry to get acoustic preparation support for cell therapies.
- Sector
- Healthcare
- HQ
- Mitry-Mory, France
- Employees
- 16
- Website
- aenitis.fr/
- Ownership
- Privately Held (backing)
Aenitis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aenitis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aenitis in its N-PORT filings yet. We sweep new filings monthly.